Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | C1S | P09871 | 1/20 | 0.39 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24063666 | 0.78 | — | — | |
| SCHEMBL11125667 | 0.76 | PRSS1 (0.45) | PRSS1PRSS2PRSS3C1SSLC11A2 | |
| SCHEMBL1005550 | 0.76 | TDP1 (0.41) | — | |
| SCHEMBL27718146 | 0.73 | PRSS1 (0.38) | PRSS1PRSS2PRSS3C1SSLC11A2 | |
| SCHEMBL2182843 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL12489365 | 0.70 | KDM4E (0.40) | MAPT | |
| SCHEMBL18314954 | 0.70 | PRSS1 (0.61) | PRSS1PRSS2PRSS3C1SSLC11A2 | |
| SCHEMBL13813419 | 0.69 | SLC9A1 (0.51) | — | |
| SCHEMBL1259969 | 0.68 | KDM4E (0.38) | — | |
| SCHEMBL625521 | 0.68 | KDM4E (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279804-B | Ethylene copolymers and catalyst mixtures for making ethylene copolymers | 阿朗新科荷兰有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-111989336-B | Metal complexes comprising amidine and indole fused cyclopentadienyl ligands | 阿朗新科荷兰有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | UDC IRELAND LIMITED (IE) | 2021-11-30 | — | — | US | disclosed |
| CN-112703208-A | Catalyst mixture | 阿朗新科荷兰有限公司 | 2021-04-23 | — | — | CN | disclosed |
| CN-111989336-A | Metal complexes comprising amidine and indole fused cyclopentadienyl ligands | 阿朗新科荷兰有限公司 | 2020-11-24 | — | — | CN | disclosed |
| CN-111527095-A | Metal complexes comprising amidine and thiophene fused cyclopentadienyl ligands | 阿朗新科荷兰有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-107922529-B | Catalyst system | 阿朗新科荷兰有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106687468-B | Metal complexes comprising amidines and substituted cyclopentadienyl ligands | 阿朗新科荷兰有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10543280-B2 | Stabilization of biomolecules using sugar polymers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2807177-B1 | STABILIZATION OF BIOMOLECULES USING SUGAR POLYMERS | UNIV CALIFORNIA (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-1932834-A1 | Aromatic 1,4-DI-Carboxylamides and their use | The Genetics Company, Inc. (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070212299-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7226594-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1537140-A4 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1638588-A1 | P-SELECTIN TARGETING LIGAND AND COMPOSITIONS THEREOF | Astellas Pharma Inc. (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1537140-A2 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | Agensys, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004105783-A1 | P-SELECTIN TARGETING LIGAND AND COMPOSITIONS THEREOF | ASTELLAS PHARMA, INC. (JP) | 2004-12-09 | — | — | WO | disclosed |
| US-20030206905-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003040340-A9 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003040340-A2 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543280-B2 | Stabilization of biomolecules using sugar polymers | TREH, HBG1, SMURF1 | PRSS1 1066/4885PRSS2 534/4885PRSS3 422/4885 |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | OCIAD2, OCIAD1, CLTB | PRSS1 3604/4885PRSS2 3248/4885PRSS3 3375/4885 |
| US-20070212299-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | DCLRE1B, PABPC1, PABPC4 | PRSS1 1568/4885PRSS2 2331/4885PRSS3 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.